MECHANISM OF ACTION
- For diabetic macular edema (DME)
- For macular edema following branch retinal vein occlusion (BRVO)
or central retinal vein occlusion (CRVO) - For noninfectious posterior segment uveitis
Ozurdex® targets multiple inflammatory cytokines
- OZURDEX® is a sustained-release, biodegradable steroid implant containing dexamethasone, a corticosteroid4
- Dexamethasone has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased4:
- Edema
- Fibrin deposition
- Capillary leakage
- Migration of inflammatory cells
see how ozurdex® works to treat Diabetic Macular Edema (DME)
See 3-year clinical efficacy
go
see how ozurdex® works to treat macular edema following RVO (BRVO or CRVO)
how ozurdex® works in noninfectious posterior segment uveitis
- Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells4
- In noninfectious posterior segment uveitis, evidence suggests that inhibition of the cytokine NF-kB plays a key role in suppression of inflammation7
novadur® technology:
a proprietary drug delivery system
- A sustained-release, biodegradable steroid implant4
- Solid polymer matrix contains 0.7 mg of dexamethasone, a corticosteroid4
- Biodegrades to lactic acid and glycolic acid4
- Administered by injection as an in-office procedure4
Tiny
implant
implant
Before
implantation
implantation
3 weeks
after implantation
after implantation
Scanning electron microscopy (SEM) magnification of implant surface in an animal model.
Clinical significance unknown.3
A patented
intravitreal applicator
- Sterile, single-use applicators are supplied preloaded with an implant4
- Includes second-generation needle
- Implants are administered using a shelved injection technique4
See how the ozurdex® applicator works
Click here to access injection technique educational resources.
